Merida Biosciences
Last verified 2026-05-26. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $121.0Mattributed |
|---|---|
| Latest round | series-a, $121.0M, 2025-04-01attributed |
| Founded | 2025 |
| Headquarters | US |
| Industry | unknown |
| Stage | series-a |
| Website | meridabiosciences.com |
Merida Biosciences develops precision therapeutics that selectively eliminate the pathogenic antibodies driving autoimmune and allergic diseases. It targets patients with conditions such as Graves' disease, allergy, and membranous nephropathy. Its protein engineering platform flags antibodies for natural clearance without broad immunosuppression.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-04-01 | series-a | $121.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $121.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $121.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | meridabiosciences.com, read 2026-05-26 |
| Description | self-reported | meridabiosciences.com, read 2026-05-26 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.